The ReMATCH Study is a prospective, single arm, open label, multi-center, study utilizing the FARAPULSE PFA System, including the FARAWAVE and FARAPOINT PFA Catheters.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Primary safety endpoint rate
Timeframe: 60 days
The primary effectiveness endpoint is the proportion of Treatment subjects with Acute Procedural Success.
Timeframe: 24 hours